Zytiga™ (Abiraterone Acetate)

A first-in-class oral CYP17 inhibitor proposed initially for use in combination with prednisone to treat metastatic castration-resistant prostate cancer (CRPC) in patients previously treated with a docetaxel chemotherapy. If you have a Hayes login, click here to...